Diabetes drug tested to boost cancer treatment
NCT ID NCT05487859
Summary
This study aimed to see if adding acarbose, a common diabetes medication, to standard immunotherapy is safe and tolerable for people with advanced kidney cancer that has spread. Researchers also wanted to check if acarbose changes the gut's bacteria (microbiome) and if the combination helps control the cancer longer. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.